Related references
Note: Only part of the references are listed.Satin therapy increases lipoprotein(a) levels
Sotirios Tsimikas et al.
EUROPEAN HEART JOURNAL (2020)
A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels
Ye-Xuan Cao et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2019)
PCSK9 inhibitors: clinical evidence and implementation
Marc S. Sabatine
NATURE REVIEWS CARDIOLOGY (2019)
Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia
Valentin Blanchard et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2019)
Genetic Factors Explain a Major Fraction of the 50% Lower Lipoprotein(a) Concentrations in Finns
Gertraud Erhart et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins Prespecified Secondary End Points in ORION 1
Kausik K. Ray et al.
CIRCULATION (2018)
PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate
Mikael Croyal et al.
CLINICAL SCIENCE (2018)
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
Gerald F. Watts et al.
EUROPEAN HEART JOURNAL (2018)
Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study
Valentin Blanchard et al.
JOURNAL OF LIPID RESEARCH (2018)
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Stable Isotope Kinetic Study of ApoM (Apolipoprotein M)
Mikael Croyal et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects
Renu Nandakumar et al.
JOURNAL OF LIPID RESEARCH (2018)
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
Gissette Reyes-Soffer et al.
CIRCULATION (2017)
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
Gerald F. Watts et al.
CIRCULATION (2017)
Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study
Shinichi Oikawa et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2017)
Effect of APOE ε Genotype on Lipoprotein(a) and the Associated Risk of Myocardial Infarction and Aortic Valve Stenosis
Leonard Kritharides et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9
Jonathan B. Edmiston et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab
Byambaa Enkhmaa et al.
JOURNAL OF LIPID RESEARCH (2017)
Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E
John S. Millar et al.
JOURNAL OF LIPID RESEARCH (2017)
A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms
Salome Mack et al.
JOURNAL OF LIPID RESEARCH (2017)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature
Ellie Paige et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype An Analysis of 431 239 Patients
Patrick M. Moriarty et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies
Gilles Lambert et al.
CLINICAL SCIENCE (2017)
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations
Hayato Tada et al.
CIRCULATION JOURNAL (2016)
Multiplexed peptide analysis for kinetic measurements of major human apolipoproteins by LC/MS/MS
Mikael Croyal et al.
JOURNAL OF LIPID RESEARCH (2016)
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role
Frederick J. Raal et al.
JOURNAL OF LIPID RESEARCH (2016)
Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA
Johannes Kettunen et al.
NATURE COMMUNICATIONS (2016)
Effects of Extended-Release Nicotinic Acid on Apolipoprotein ( a) Kinetics in Hypertriglyceridemic Patients
Mikael Croyal et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100-Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus
Esther M. Ooi et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
Paul N. Hopkins et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
Rocco Romagnuolo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
Paul N. Hopkins et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
Lipoprotein(a) metabolism
Stefania Lamon-Fava et al.
CURRENT OPINION IN LIPIDOLOGY (2014)
Absolute quantification of apolipoproteins and associated proteins on human plasma lipoproteins
Anne von Zychlinski et al.
JOURNAL OF PROTEOMICS (2014)
Lipoprotein(a) metabolism: Potential sites for therapeutic targets
Jane Hoover-Plow et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome
Esther M. M. Ooi et al.
JOURNAL OF LIPID RESEARCH (2012)
Proteomics of Lipoprotein(a) identifies a protein complement associated with response to wounding
Anne von Zychlinski et al.
JOURNAL OF PROTEOMICS (2011)
PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
Bertrand Cariou et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism
John S. Millar et al.
JOURNAL OF LIPID RESEARCH (2008)
Design and analysis of lipoprotein tracer kinetics studies in humans
P. Hugh et al.
JOURNAL OF LIPID RESEARCH (2006)
Influence of atorvastatin on apolipoprotein E and Al kinetics in patients with type 2 diabetes
K Bach-Ngohou et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients - Impact of change in triglyceride level and liver function
HS Ko et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2005)
Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9
K Ouguerram et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency
K Ikewaki et al.
JOURNAL OF LIPID RESEARCH (2004)
Diabetic dyslipidaemia: from basic research to clinical practice
MR Taskinen
DIABETOLOGIA (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia
JS Cohn et al.
JOURNAL OF LIPID RESEARCH (2002)
Share Paper
